Keine Story von Medicago mehr verpassen.
  • 26.09.2017 – 13:02

    Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine

    Québec City (ots/PRNewswire) - The first plant-based seasonal flu vaccine candidate reaches final clinical stage Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, is proud to announce the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. ...

  • 21.12.2009 – 13:01

    Medicago Reports Positive Phase I Results for its Avian Flu Pandemic Vaccine

    Quebec City (ots/PRNewswire) - Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The ...